1.
Wadden T, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C, et al. LIRAGLUTIDE 3.0 mg AS AN ADJUNCT TO INTENSIVE BEHAVIOR THERAPY IN INDIVIDUALS WITH OBESITY: SCALE IBT 56-WEEK RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED TRIAL. J ASEAN Fed Endocr Soc [Internet]. 2022 May 4 [cited 2024 Nov. 21];34(2):9-10. Available from: https://asean-endocrinejournal.org/index.php/JAFES/article/view/1853